Tamoxifen
Soltamox, Tamoxifen (tamoxifen) is a small molecule pharmaceutical. Tamoxifen was first approved as Nolvadex on 1982-01-01. It is used to treat breast neoplasms, gynecomastia, pancreatic neoplasms, and precocious puberty in the USA. The pharmaceutical is active against estrogen receptor. In addition, it is known to target G-protein coupled estrogen receptor 1 and estrogen receptor beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Soltamox (generic drugs available since 2003-02-20, discontinued: Nolvadex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tamoxifen citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SOLTAMOX | MAYNE PHARMA COMMRCL | N-021807 RX | 2005-10-29 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| soltamox | New Drug Application | 2021-11-29 |
| tamoxifen citrate | ANDA | 2024-01-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0187 | Tamoxifen citrate, oral, 10 mg |
Clinical
Clinical Trials
543 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 30 | 136 | 127 | 13 | 80 | 375 |
| Hot flashes | D019584 | — | — | 1 | 3 | 1 | 1 | 3 | 9 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 1 | 2 | 1 | 1 | 6 |
| Infertility | D007246 | HP_0000789 | — | — | — | 1 | 1 | 1 | 3 |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | — | — | — | 2 | — | 2 |
| Menstruation disturbances | D008599 | HP_0400007 | N91.5 | — | — | — | 1 | — | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | 1 | — | 1 |
| Medicated intrauterine devices | D007436 | — | — | — | — | — | 1 | — | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | 1 | — | 1 |
| Sexuality | D019529 | — | — | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male breast neoplasms | D018567 | — | — | 1 | 9 | 6 | — | 4 | 20 |
| Neoplasms | D009369 | — | C80 | 4 | 4 | 2 | — | 2 | 12 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | 7 | 2 | — | — | 11 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 2 | 2 | — | 5 | 9 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 5 | 1 | — | — | 8 |
| Ductal carcinoma breast | D018270 | — | — | 1 | 3 | 2 | — | 1 | 7 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 3 | — | 3 | 6 |
| Fallopian tube neoplasms | D005185 | — | — | — | 2 | 2 | — | — | 4 |
| Intraductal carcinoma noninfiltrating | D002285 | — | D05.1 | — | 2 | 1 | — | 1 | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | 2 | — | — | 4 |
Show 28 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | — | 5 | — | — | — | 5 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 3 | — | — | — | 3 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | 3 | — | — | — | 3 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | — | — | 2 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | 1 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 2 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
| Aggressive fibromatosis | D018222 | — | D48.11 | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Postmenopause | D017698 | — | — | — | — | — | — | 2 | 2 |
| Hodgkin disease | D006689 | — | C81 | — | — | — | — | 2 | 2 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | — | — | — | 2 | 2 |
| Systemic mastocytosis | D034721 | — | C96.21 | — | — | — | — | 1 | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Fertility | D005298 | — | — | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tamoxifen |
| INN | tamoxifen |
| Description | Tamoxifen is a tertiary amino compound and a stilbenoid. It has a role as an estrogen receptor antagonist, a bone density conservation agent, an estrogen receptor modulator, an estrogen antagonist, an angiogenesis inhibitor, an EC 2.7.11.13 (protein kinase C) inhibitor, an EC 1.2.3.1 (aldehyde oxidase) inhibitor and an antineoplastic agent. It derives from a hydride of a stilbene. |
| Classification | Small molecule |
| Drug class | Selective estrogen receptor modulator |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 10540-29-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL83 |
| ChEBI ID | 41774 |
| PubChem CID | 2733526 |
| DrugBank | DB00675 |
| UNII ID | 094ZI81Y45 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ESR2
ESR2
CES1
CES1
Organism
Homo sapiens
Gene name
ESR2
Gene synonyms
ESTRB, NR3A2
NCBI Gene ID
Protein name
estrogen receptor beta
Protein synonyms
estrogen receptor beta 2, estrogen receptor beta 4, Nuclear receptor subfamily 3 group A member 2, oestrogen receptor beta
Uniprot ID
Mouse ortholog
Esr2 (13983)
estrogen receptor beta (O08537)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Tamoxifen
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 94,561 documents
View more details
Safety
Black-box Warning
Black-box warning for: Soltamox, Tamoxifen citrate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,451 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use